Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its entry into a research and development collaboration with ATERA SAS of France, a leading tissue engineering company specializing in the development of advanced human tissue models. Under the terms of the agreement, ATERA will develop 3D human skin models of Epidermolysis Bullosa (EB) to be used in the evaluation of INM-750, InMed’s proprietary topical cannabinoid product candidate targeted as a therapy in EB and other potential dermatological and wound-healing applications. “INM-750 has demonstrated significant potential in pre-clinical models to address symptomatic improvement of EB including accelerated wound healing and a reduction in pain, itch and inflammation,” Dr. Sazzad Hossain, CSO of InMed, stated in the news release. “This project with ATERA is designed to assess the potential of INM-750 to have an impact in disease reversal, further supporting our current data indicating an up-regulation in specific keratins in the skin. By utilizing full-thickness skin models derived from EB skin samples, we can better validate INM-750’s target effect and efficacy in vitro ahead of our upcoming clinical trial program.”
To view the full press release, visit http://nnw.fm/aLE0Q
About InMed
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
Read More